Nonunions occur in approximately 5 percent of patient fracture cases each year. Nonunions have little expectation of spontaneous healing and can be corrected with revision surgery, however such procedures typically pose technical challenges and an increased potential for complications. When surgery is optional and patients want to avoid its associated risks, choosing LIPUS has demonstrated a positive healing effect more than 80 percent of the time, which is comparable to the success rate for surgical treatment.
“This meta-analysis revealed that LIPUS is a viable alternative to surgery for established nonunions,” said Dr. R. Grant Steen, manager of medical affairs for Bioventus. “The heal rate across all primary studies included was 82% and increased to 84% for nonunions that were eight months or older.”
The review and meta-analysis was funded by Bioventus and adhered to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Studies were considered eligible for review if LIPUS was used as an alternative to surgery for non-healing fractures and if the treatment was applied at least three months after the last surgical procedure. In addition, at least one outcome of interest (heal/fail) was required and a clear definition of delayed or nonunion was included.
Authors of this study include Ross Leighton, M.D., Dalhousie University; J. Tracy Watson, M.D., Saint Louis University School of Medicine; Peter Giannoudis, M.D., University of Leeds; Costas Papakostidis, M.D., Chapel Allerton Hospital; Andrew Harrison, Ph.D., Bioventus and R. Grant Steen, Ph.D., Bioventus.
Bioventus is an orthobiologics company that delivers products that help people heal quickly and safely. Its mission is to make a difference by helping patients resume and enjoy active lives. The company has two product portfolios for orthobiologics, Bioventus Active Healing Therapies and Bioventus Surgical that make it a global leader in active orthopaedic healing. Its EXOGEN® Ultrasound Bone Healing System uses safe, effective low intensity pulsed ultrasound (LIPUS) to stimulate the body’s natural healing process. EXOGEN has been used to treat more than 1 million patients worldwide and numerous regulatory agencies including the U.S. Food and Drug Administration, Health Canada, BSi, Therapeutic Goods Administration, Medsafe, UAE Ministry of Health and SFDA have granted their approval of the product.